97 related articles for article (PubMed ID: 16487703)
21. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
[TBL] [Abstract][Full Text] [Related]
22. An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors.
Nicolotti O; Miscioscia TF; Carotti A; Leonetti F; Carotti A
J Chem Inf Model; 2008 Jun; 48(6):1211-26. PubMed ID: 18540590
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY
J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785
[TBL] [Abstract][Full Text] [Related]
24. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of Factor VIIa/tissue factor.
Shirk RA; Vlasuk GP
Arterioscler Thromb Vasc Biol; 2007 Sep; 27(9):1895-900. PubMed ID: 17600222
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and discovery of a novel pyrazole derivative as an inhibitor of apoptosis through modulating integrin beta4, ROS, and p53 levels in vascular endothelial cells.
Zhao BX; Zhang L; Zhu XS; Wan MS; Zhao J; Zhang Y; Zhang SL; Miao JY
Bioorg Med Chem; 2008 May; 16(9):5171-80. PubMed ID: 18362074
[TBL] [Abstract][Full Text] [Related]
27. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
29. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
Li YL; Fevig JM; Cacciola J; Buriak J; Rossi KA; Jona J; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Oct; 16(19):5176-82. PubMed ID: 16870435
[TBL] [Abstract][Full Text] [Related]
30. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
32. Computer based design, synthesis and biological evaluation of novel indole derivatives as HCV NS3-4A serine protease inhibitors.
Ismail NS; El Dine RS; Hattori M; Takahashi K; Ihara M
Bioorg Med Chem; 2008 Sep; 16(17):7877-87. PubMed ID: 18752958
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and preliminary biological evaluation of novel ethyl 1-(2'-hydroxy-3'-aroxypropyl)-3-aryl-1H-pyrazole-5-carboxylate.
Wei F; Zhao BX; Huang B; Zhang L; Sun CH; Dong WL; Shin DS; Miao JY
Bioorg Med Chem Lett; 2006 Dec; 16(24):6342-7. PubMed ID: 17000107
[TBL] [Abstract][Full Text] [Related]
34. Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.
Shiraishi T; Kadono S; Haramura M; Kodama H; Ono Y; Iikura H; Esaki T; Koga T; Hattori K; Watanabe Y; Sakamoto A; Yoshihashi K; Kitazawa T; Esaki K; Ohta M; Sato H; Kozono T
Bioorg Med Chem Lett; 2008 Aug; 18(16):4533-7. PubMed ID: 18674905
[TBL] [Abstract][Full Text] [Related]
35. Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.
Qiao JX; Cheng X; Smallheer JM; Galemmo RA; Drummond S; Pinto DJ; Cheney DL; He K; Wong PC; Luettgen JM; Knabb RM; Wexler RR; Lam PY
Bioorg Med Chem Lett; 2007 Mar; 17(5):1432-7. PubMed ID: 17174550
[TBL] [Abstract][Full Text] [Related]
36. Application of molecular connectivity and electro-topological indices in quantitative structure-activity analysis of pyrazole derivatives as inhibitors of factor Xa and thrombin.
Krishnasamy C; Raghuraman A; Kier LB; Desai UR
Chem Biodivers; 2008 Dec; 5(12):2609-20. PubMed ID: 19089820
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
[TBL] [Abstract][Full Text] [Related]
38. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Chan MY; Cohen MG; Dyke CK; Myles SK; Aberle LG; Lin M; Walder J; Steinhubl SR; Gilchrist IC; Kleiman NS; Vorchheimer DA; Chronos N; Melloni C; Alexander JH; Harrington RA; Tonkens RM; Becker RC; Rusconi CP
Circulation; 2008 Jun; 117(22):2865-74. PubMed ID: 18506005
[TBL] [Abstract][Full Text] [Related]
39. The first X-ray crystal structure of the glucocorticoid receptor bound to a non-steroidal agonist.
Madauss KP; Bledsoe RK; Mclay I; Stewart EL; Uings IJ; Weingarten G; Williams SP
Bioorg Med Chem Lett; 2008 Dec; 18(23):6097-9. PubMed ID: 18952422
[TBL] [Abstract][Full Text] [Related]
40. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
